Summary of Clinical Use

Concizumab was advanded to clinical evaluation as a prophylactic treatment for both hemophilia A and B. Non-fatal thrombotic events in Phase 3 study participants led to the suspension of concizumab trials in March 2020. By August 2020 the clinical hold on the trials was lifted and the trials were allowed to resume with new safety measures and guidelines in place. The EMA's orphan drug designation for the treatment of hemophilia B (issued in 2017) was withdrawn in December 2022. Concizumab was granted its first global approval by Health Canada in March 2023; for the treatment of hemophilia B [5].

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT04082429	Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors	Phase 3 Interventional	Novo Nordisk A/S	Known as the EXPLORER 6 study.
NCT04083781	Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors	Phase 3 Interventional	Novo Nordisk A/S	Known as the EXPLORER 7 study.
NCT03196284	A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors	Phase 2 Interventional	Novo Nordisk A/S		6
NCT03196297	A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors	Phase 2 Interventional	Novo Nordisk A/S		6